DPP4 and type 2 diabetes mellitus: Several experimental and clinical researches revealed that T2DM patients who were treated with DPP-4 inhibitors had lower risks for cardiovascular diseases as compared to those treated without DPP-4 inhibitors, except for metformin users [33], and DPP-4 inhibitors did not increase the risk of heart failure compared with sulfonylurea [34].